Abstract: An apparatus for vulcanizing at least a tread of a tire has a top mold section and a bottom mold section. The mold sections are secured to one another during a vulcanizing process by a plurality of locking mechanisms located around the outer circumference of the apparatus. Each locking mechanism includes a dual action hydraulic actuator. A piston rod of the hydraulic actuator imparts movement to a generally vertically oriented articulated linkage member. T-shaped projection located at an end of the articulated linkage member distal from the piston rod is brought into engagement with a securing member associated with the top mold section to secure the mold sections to one another. After the vulcanizing process is complete the hydraulic actuator imparts movement to the articulated linkage member to release the top mold section from the bottom mold section.

Abstract: A container for storing, securing and transporting articles. The container comprises a plurality of members having predetermined lengths. A plurality of connectors interconnect the members to space apart and arrange the members generally vertically and horizontally to form a boxlike shape. A selectably securable closure is hingedly coupled to a first sidewall of the container. A pair of wheels are attached to a first edge of a bottom of the container, and a pair of legs attached to a second, opposing edge of the bottom of the container. The container may be stored in either a generally vertical orientation or a generally horizontal orientation. The container may also be pivoted about the wheels to transport the container. In addition, the container may be stacked with other containers when in the horizontal orientation.

Abstract: A composition or vaccine composition comprising at least one peptide that has less than 600 contiguous amino acids having 100% identity to a native sequence of CEA, HER2/neu, MAGE2, MAGE3, or p53, the peptide further comprising at least one epitope selected from Table 6.

Abstract: This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to identify and prepare prostate cancer-associated antigen epitopes, and to develop epitope-based vaccines directed towards prostate tumors. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and treatment of cancer.

Abstract: A peptide or composition comprising at least one epitope or analog from CEA, HER2/neu, MAGE2, MAGE3, or p53.

Abstract: Heteroclitic analogs of class I epitopes are prepared by providing conservative, semi-conservative, or non-conservative amino acid substitutions at positions 3 and/or 4 and/or 5 and/or 6 and/or 7 and/or 8 and/or 9 and/or 10 of these epitopes. The analogs are useful in eliciting immune responses with respect to the corresponding wild-type epitopes.

Abstract: This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to identify and prepare p53 epitopes, and to develop epitope-based vaccines directed towards p53-bearing tumors. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and treatment of cancer.

Abstract: A method for performing a fibre channel arbitrated loop integrity test using a fibre channel switch element is provided. The method includes, sending a fibre channel frame through the arbitrated loop; receiving the fibre channel frame after it has traversed through the arbitrated loop; performing a data compare between the fibre channel frame that was sent and the fibre channel frame that is received; detecting internal errors, if any, in the traversed fibre channel loop; and isolating a module that may have generated the error. The switch element includes, a cascade port that is used to couple one fibre channel switch element to another in a loop; and a port that sends a fibre channel frame through the loop and detects internal errors based on the comparison and a isolates a module that may have generated the internal error.

Abstract: A fiber channel switch element that can generate a character or frame based test pattern is provided. The switch element includes a buffer that can be coupled to a transmission protocol engine for sending and receiving data to and from a fiber channel network, wherein the buffer is programmed to generate character or fiber channel frames for testing plural links coupled to the fiber channel switch element while operating in a character or frame mode. The buffer can be coupled to a receive or transmit path and generates characters or frames based on a programmed count to induce real-time errors. The real-time errors include a missing start of frame (“SOF”) and a missing end of frame (“EOF”).

Abstract: A method and fibre channel switch element is provided for isolating a defective device that is coupled to a fibre channel arbitrated loop. The method includes, isolating a port if a loop initialization primitive (“LIP”) is detected from a device coupled to the arbitrated loop; configuring the device and acquiring an AL_PA; determining if the device is sending LIPs; and isolating the device if the device continues to send LIPs. The switch element includes, a port having an isolation state machine that allows the switch element to isolate a device whose behavior may result in disruption of other devices in the network. The state machine may also configure a device after detecting disruptive parameters from the device and perform diagnostic operations on the device.

Abstract: A fibre channel switch element with an acceleration device that connects plural fibre channel devices in an arbitrated loop and monitors frames sent during a loop initialization process is provided. The acceleration device creates an AL_PA table selected by each fibre channel device, wherein the AL_PA table is used for port selection; and during an arbitration process sends a benign primitive to non-arbitrating devices. The acceleration device includes, a global arbitration module, a state machine module, and a matrix for connecting plural fibre channel devices.

Abstract: A method and system for detecting orphaned CLS primitives in a fibre channel network having a fibre channel switch element coupled to an arbitrated loop is provided. The method includes, sending an OPN primitive to a switch element port's own AL_PA to open a connection with itself; and determining if a CLS primitive is received within a loop a latency period. If a CLS primitive is received within the latency period then the CLS primitive is classified as an orphan and the orphaned CLS primitive is removed by the switch element by enabling a firmware based removal feature. The switch element includes a port that arbitrates for the arbitrated loop ownership and sends an OPN primitive to its own AL_PA.

Abstract: This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to identify and prepare carcino-embryonic antigen (CEA) epitopes, and to develop epitope-based vaccines directed towards CEA-bearing tumors. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and treatment of cancer.

Abstract: This invention uses our knoeledge of the mechanisms by which antigen is recognized by T cells to identify and prepare HER2/neu epitopes, and to develop epitope-based vaccines directed towards HERS2/neu-bearing tumors. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and treatment of cancer.

Abstract: The invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to identify and prepare MAGE2/3 epitopes, and to develop epitope-based vaccines directed towards MAGE2/3-bearing tumors. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use it) the prevention and treatment of cancer.

Abstract: This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to identify and prepare p53 epitopes, and to develop epitope-based vaccines directed towards p53-bearing tumors. More specifically, this application communicates our discovery of pharmnaceutical compositions and methods of use in the prevention and treatment of cancer.

Abstract: This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to identify and prepare prostate cancer-associated antigent epitopes, and to develop epitope-based vaccines directed towards prostate tumors. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and treatment of cancer.

Abstract: This invention uses our knoeledge of the mechanisms by which antigen is recognized by T cells to identify and prepare HER2/neu epitopes, and to develop epitope-based vaccines directed towards HERS2/neu-bearing tumors. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and treatment of cancer.